期刊文献+

重症肌无力Osserman Ⅴ型1例临床及病理分析 被引量:1

原文传递
导出
摘要 目的报道1例Osserman Ⅴ型重症肌无力患者,讨论其临床和肌肉病理特点。方法对1例Osserman Ⅴ型重症肌无力患者的临床特点进行回顾性分析,对患者行右侧肱二头肌的活体组织病理检查。结果该患者临床早期出现肌肉萎缩,球部症状明显。肌肉活检可见轻微肌源性和神经源性改变,同时合并有微血管病变。结论 Osserman Ⅴ型重症肌无力发病率低,充分认识其临床特点及肌肉病理特征,有利于提高诊断率,预测预后及合理治疗。
出处 《卒中与神经疾病》 2010年第3期174-176,共3页 Stroke and Nervous Diseases
  • 相关文献

参考文献10

  • 1Natsuko Yuki,Akira Yoshioka,Reina Isayama,et al.Facial Muscular Atrophy in a Myasthenia Gravis Patient.Inter Med,2008,47(14):1355-1357.
  • 2王化冰,刘明生,管宇宙,崔丽英.Osserman V型重症肌无力5例临床分析及文献复习[J].中国神经免疫学和神经病学杂志,2007,14(6):317-319. 被引量:6
  • 3宋林,姜亚平,汪春娟,彭圣威,杨明山.重症肌无力Osserman Ⅴ型2例报道[J].卒中与神经疾病,2005,12(3):185-186. 被引量:6
  • 4Neli Boneva,Melinee Frenkian-Cuvelier a,Jocelyne Bidault,et al.Major pathogenic effects of anti-MuSK antibodies in Myasthenia Gravis.Journal of Neuroimmunology 2006,177(1-2):119-131.
  • 5S.Martignago,M.Fanin,E.Albertini,et al.Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR.Neuropathology and Applied Neurobiology 2009,35(1),103-110.
  • 6王化冰,刘明生,崔丽英.重症肌无力抗肌肉特异性酪氨酸受体激酶抗体阳性一例[J].中华神经科杂志,2006,39(5):354-354. 被引量:5
  • 7Wataru Ishii,Masayuki Matsuda,Naoko Okamoto,et al.Myasthenia Gravis with Anti-MuSK Antibody,Showing Progressive Muscular Atrophy without Blepharoptosis.Internal Medicine 2005,44,(6):671-672.
  • 8Oosterhuis H,Bethlem J.Neurogenic muscle involvement in myasthenia gravis.A clinical and histopathological study.J Neurol Neurosurg Psychiatry 1973,36(2):244-254.
  • 9Maria E Farrugia,Robin P Kennett,David Hilton-Jones,et al.Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies.Clinical Neurophysiology 2007,118(2):269-277.
  • 10Mendell JR,Garcha TS,Kissel JT.The immunopathogenic role of complement in human muscle disease.Curr Opin Neurol.1996,9(3):226-234.

二级参考文献20

  • 1宋林,姜亚平,汪春娟,彭圣威,杨明山.重症肌无力Osserman Ⅴ型2例报道[J].卒中与神经疾病,2005,12(3):185-186. 被引量:6
  • 2刘卫彬,夏强,门丽娜,黄如训.以声带麻痹为突出表现的重症肌无力七例[J].中华医学杂志,2006,86(25):1778-1780. 被引量:3
  • 3Rash JE, Hudson CS, Graham WF, et al. Freeze fracture studies of human neurimuscular junctions: Membrane alterations observed in myasthenia gravis. Lab Invest 1981, 44(6) :519-530.
  • 4Szobor A. Myasthenia Gravis. Budapest: Akabemiai Kiads,1990. 1-33.
  • 5Vincent A,Bowen J,Newsom-Davis J,et al.Seronegative generalised myasthenia gravis:clinical features,antibodies,and their targets.Lancet Neurol,2003,2:99-106.
  • 6Lavrnic D,Losen M,Vujic A,et al.The features of myasthenia gravis with autoantibodies to MuSK.J Neurol Neurosurg Psychiatry,2005,76:1099-1102.
  • 7丛志强,李大年.现代神经内科学[M].济南:山东科学技术出版社,2002,931-971.
  • 8Osserman KE. Clinical aspects[M]. In: Osserman KE. Myasthenia gravis[M]. New York,NY: Grune & Stratton, 1958,79-80.
  • 9Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America[J]. Ann Thorac Surg, 2000, 70: 327-334.
  • 10Benveniste O, Jacobson L, Farrugia ME, et al. MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo [J]. J Neuroimmunol, 2005, 170:41-48,

共引文献12

同被引文献9

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部